{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    8,
    9,
    14,
    15,
    20,
    22,
    95
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "INT-7",
        "name": "Amendment INT-7",
        "scope": {
          "id": "eeb6cca8-7397-4fcd-b5d2-11edcb28dcec",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "459afeb9-7102-488f-a6f5-073021d19c40",
          "code": {
            "id": "4bcee784-c1d6-4e30-a7a3-e69ce683cf97",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "1d2ad585-a0d6-4673-89ba-6f1ad17147e6",
            "type": {
              "id": "f2ada6f2-ba9c-416a-8bbe-c8839d1ebb14",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To update safety information to align with the ibrutinib Investigator’s Brochure (IB) to include information regarding cerebrovascular accidents as a new safety observation identified from the post-marketing setting, and to clarify that assessment of pulse/heart rate and blood pressure is expected at every protocol-specified visit until end of treatment.",
        "effectiveDate": "2019-12-19",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "INT-6",
        "newVersion": "INT-7"
      },
      {
        "id": "amend_2",
        "number": "INT-4",
        "name": "Amendment INT-4",
        "scope": {
          "id": "e065f438-ea59-4146-8a5b-994a8a138727",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "faf9c3c9-2961-4a87-9622-2e500f29401c",
          "code": {
            "id": "294446a8-f7a5-4d2f-88c3-b66dfcf754ad",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "2854cfd8-b17d-426b-858f-424bb06cd649",
            "type": {
              "id": "0a6ae263-bbb7-4928-a0ad-23a75496fa28",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The knowledge gained on the efficacy of ibrutinib from completed randomized clinical studies, which was not available at time of MCL3002 study design, and the lower than expected event rate are the key drivers for this amendment. The sponsor has added a second interim analysis to occur at approximately 180 PFS events to mitigate for the potential long interval between the planned first interim analysis (134 PFS events) and the final analysis (265 PFS events).",
        "effectiveDate": "2016-04-29",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "INT-3",
        "newVersion": "INT-4"
      },
      {
        "id": "amend_3",
        "number": "INT-3",
        "name": "Amendment INT-3",
        "scope": {
          "id": "7f9e6efb-21c5-45bf-be4f-b67f5a39b920",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "14ab6ca6-c07d-4e22-9bda-485d410ff435",
          "code": {
            "id": "07fd40a6-34c0-4e31-b1c6-b92a22b4ff84",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "a0f81058-d4d8-4d3e-bea9-ba8ef71dda1b",
            "type": {
              "id": "5bcd7ce3-9525-43ab-b464-8f4422f532f6",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To update the safety language for diarrhea and other safety topics in the Introduction, the background safety information for ibrutinib has been aligned with the recently updated ibrutinib Investigator’s Brochure (IB) and other protocols within the clinical development program.",
        "effectiveDate": "2015-08-20",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "INT-2",
        "newVersion": "INT-3"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "STATISTICAL",
        "description": "Statistical",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [],
    "studySites": [],
    "summary": {
      "amendmentCount": 3,
      "countryCount": 0,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope"
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "INT-7",
        "effectiveDate": "2019-12-19",
        "summary": "To update safety information to align with the ibrutinib Investigator’s Brochure (IB) to include information regarding cerebrovascular accidents as a new safety observation identified from the post-marketing setting, and to clarify that assessment of pulse/heart rate and blood pressure is expected at every protocol-specified visit until end of treatment.",
        "previousVersion": "INT-6",
        "newVersion": "INT-7",
        "reasons": [
          "Safety",
          "Operational"
        ]
      },
      {
        "number": "INT-4",
        "effectiveDate": "2016-04-29",
        "summary": "The knowledge gained on the efficacy of ibrutinib from completed randomized clinical studies, which was not available at time of MCL3002 study design, and the lower than expected event rate are the key drivers for this amendment. The sponsor has added a second interim analysis to occur at approximately 180 PFS events to mitigate for the potential long interval between the planned first interim analysis (134 PFS events) and the final analysis (265 PFS events).",
        "previousVersion": "INT-3",
        "newVersion": "INT-4",
        "reasons": [
          "Scientific",
          "Statistical"
        ]
      },
      {
        "number": "INT-3",
        "effectiveDate": "2015-08-20",
        "summary": "To update the safety language for diarrhea and other safety topics in the Introduction, the background safety information for ibrutinib has been aligned with the recently updated ibrutinib Investigator’s Brochure (IB) and other protocols within the clinical development program.",
        "previousVersion": "INT-2",
        "newVersion": "INT-3",
        "reasons": [
          "Safety",
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [],
      "regions": [],
      "plannedSites": null
    },
    "sites": []
  }
}